<DOC>
	<DOCNO>NCT03004612</DOCNO>
	<brief_summary>Type 2 diabetes worldwide epidemic disease , preventive strategy need face health problem . The goal clinical trial evaluate effect linagliptin + metformin v metformin alone physiopathological parameter , glucose metabolism , insulin resistance , insulin secretion pancreatic beta cell function patient impair fast glucose plus impaired glucose tolerance , 12 month .</brief_summary>
	<brief_title>Effect Linagliptin + Metformin v Metformin Alone Patients With Prediabetes</brief_title>
	<detailed_description>The main goal clinical trial compare effect two different treatment 12 month : 1 . Lifestyle modification program + metformin 850mg twice daily 2 . Lifestyle modification program + linagliptin ( 2.5mg ) metformin ( 850mg ) twice daily follow parameter , 12 month treatment : 1 . Glucose metabolism , evaluate oral glucose tolerance 2 . Insulin resistance , evaluate oral glucose tolerance 100 % patient hyperglycemic clamp 10 % patient 3 . Insulin secretion , evaluate oral glucose tolerance 100 % patient hyperglycemic clamp 10 % patient 4 . Pancreatic beta cell function , evaluate oral glucose tolerance 100 % patient hyperglycemic clamp 10 % patient 5 . Systemic inflammation cardiovascular risk factor , evaluate cytokine interlelukin-6 ( IL6 ) , C-reactive protein ( PCR ) , measurement intima medium thickness ultrasound . All patient basal evaluation oral glucose tolerance test , lipid profile , body composition , IMT measurement ultrasonography ; 10 % invited hyperglycemic clamp . After basal evaluation , patient result IMPAIRED FASTING GLUCOSE + IMPAIRED GLUCOSE TOLERANCE , invite intervention phase randomize one two treatment group . Patients follow-up visit every month review adherence lifestyle modification program medication . After 12 month , patient repeat evaluation perform basal evaluation .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Patients combine prediabetes , define coexistence impaired fasting glucose ( Fasting glucose 100 125 mg/dL ) impair glucose tolerance ( Glucose 140 199 mg/dL 2 hour Oral Glucose Tolerance test ( OGTT ) ) Patients accept participate study sign inform consent letter . Patients diagnose Type 2 Diabetes Mellitus previously detect OGTT Patients actual treatment last 3 month metformin , pioglitazone another antidiabetic drug , include insulin . Serum creatinine &gt; 1.6 mg/dL Hypertriglyceridemia high ( &gt; 500 mg/dL ) Pregnant woman Altered arterial hypertension ( Systolic &gt; 180 mmHg Diastolic &gt; 105 mmHg ) Excessive alcohol intake , acute chronic Medications medical condition affect glucose homeostasis ( thiazide , beta blocker , glucocorticoid systemic use , weightreducing drug anorexigenics , Cushing 's syndrome , Thyrotoxicosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>prediabetes</keyword>
</DOC>